Few FDA concerns for Novo's liraglutide in obesity
This article was originally published in Scrip
Executive Summary
Things appear mostly positive for Novo Nordisk going into the 11 September meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) for the review of the company's glucagon-like-peptide (GLP-1) liraglutide for use as a weight-loss medication, with the drug meeting the efficacy standards for that indication and most of its adverse effects already a matter of record.